| scholarly article | Q13442814 |
| P50 | author | Anna Maria Rachiglio | Q41907329 |
| Vincenzo Sforza | Q56953948 | ||
| Claudia Cardone | Q87293374 | ||
| P2093 | author name string | Fortunato Ciardiello | |
| Floriana Morgillo | |||
| Nicola Normanno | |||
| Evaristo Maiello | |||
| Maurizio Di Bisceglie | |||
| Alfonso Reginelli | |||
| Salvatore Cappabianca | |||
| Michele Orditura | |||
| Teresa Troiani | |||
| Erika Martinelli | |||
| Anna Capasso | |||
| Stefania Napolitano | |||
| Giulia Martini | |||
| Anna Nappi | |||
| Fernando De Vita | |||
| Tiziana Pia Latiano | |||
| P2860 | cites work | Cancer statistics, 2016 | Q29547383 |
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
| Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. | Q36078348 | ||
| AXL is an oncotarget in human colorectal cancer. | Q36414168 | ||
| Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. | Q36841039 | ||
| Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial | Q38385410 | ||
| Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial | Q40931820 | ||
| Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity | Q42775676 | ||
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. | Q52861120 | ||
| P433 | issue | 3 | |
| P921 | main subject | colorectal cancer | Q188874 |
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | e000177 | |
| P577 | publication date | 2017-07-29 | |
| P1433 | published in | ESMO Open | Q53951848 |
| P1476 | title | Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment | |
| P478 | volume | 2 |
| Q57059367 | A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer |
| Q55294897 | Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. |
| Q64245602 | Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition) |
| Q90291956 | Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer |
| Q92664137 | Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report |
| Q55518346 | PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. |
| Q55088555 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. |
Search more.